The relationship between the history of PDE5-inhibitors assumption and melanoma: a systematic review
Author:
Cilio Simone1, Briatico Giulia2, Brancaccio Gabriella2, Capone Federico1, Ferro Matteo3, Imbimbo Ciro1, Salonia Andrea4, Argenziano Giuseppe2, Crocetto Felice1
Affiliation:
1. Department of Neurosciences, Reproductive Sciences and Odontostomatology , Urology Unit, University of Naples “Federico II” , Naples , Italy 2. Dermatology Unit, University of Campania , Naples , Italy 3. Division of Urology, European Institute of Oncology , Milan , Italy 4. Division of Experimental Oncology/Unit of Urology, URI, IRCCS Ospedale San Raffaele , Milan , Italy
Abstract
Abstract
Introduction
Phosphodiesterase 5 inhibitors (PDE5-is) are used worldwide as first line therapy for erectile dysfunction (ED). Current literature reported data on the warning association between PDE5-is use and the development of cutaneous melanoma. However, these data are contrasting, thus we aim to summarise evidence regarding this association.
Content
A systematic review of all published articles related to the effects of PDE5-is in the development of cutaneous melanoma was performed. PubMed, EMBASE, and Cochrane library were queried for all the published studies indexed up to the 26th of May 2023. A combination of keywords related to PDE5-is and melanoma were used. Only original studies based on human subjects in the English language were included in the analysis.
Summary and Outlook
Of 505 articles identified, only eight original articles were considered for further analysis. Overall, five of the selected articles including 657,984 subjects agrees on an increased risk of developing melanoma in PDE5-is users. On the other hand, three original articles based on data regarding 360,915 subjects, disagree with the previous statement declaring any association between PDE5-i use and melanoma. Current literature still reports contrasting data regarding the association between PDE5-is assumption and increased risk of melanoma, but a possible association is described, bringing attention to higher risk melanoma category of patients. More clinical studies are needed to clarify the impact of PDE5-is in the development and progression of melanoma.
Publisher
Walter de Gruyter GmbH
Subject
Drug Discovery,Pharmacology,General Medicine,Physiology
Reference21 articles.
1. Salonia, A, Bettocchi, C, Boeri, L, Capogrosso, P, Carvalho, J, Cilesiz, NC, et al.. European association of urology guidelines on sexual and reproductive health—2021 update: male sexual dysfunction. Eur Urol 2021;80:333–57. https://doi.org/10.1016/j.eururo.2021.06.007. 2. Giuliano, F, Montorsi, F, Mirone, V, Rossi, D, Sweeney, M. Switching from intracavernous prostaglandin E1 injections to oral sildenafil citrate in patients with erectile dysfunction: results of a multicenter European study. The Sildenafil Multicenter Study Group. J Urol 2000;164:708–11. https://doi.org/10.1097/00005392-200009010-00021. 3. Capece, M, Montorio, D, Comune, C, Aveta, A, Melchionna, A, Celentano, G, et al.. Retinal and optic disc vascular changes in patients using long-term tadalafil: a prospective non-randomized matched-pair study. Diagn Basel Switz 2021;11:802. https://doi.org/10.3390/diagnostics11050802. 4. Giuliano, F, Jackson, G, Montorsi, F, Martin-Morales, A, Raillard, P. Safety of sildenafil citrate: review of 67 double-blind placebo-controlled trials and the postmarketing safety database. Int J Clin Pract 2010;64:240–55. https://doi.org/10.1111/j.1742-1241.2009.02254.x. 5. Pezone, G, Collà Ruvolo, C, Cilio, S, Fraia, A, Di Mauro, E, Califano, G. The spreading information of YouTube videos on Phosphodiesterase 5 inhibitors: a worrisome picture from one of the most consulted internet source. Int J Impot Res 2023.
|
|